Literature DB >> 25261908

The comparison of miR-155 with computed tomography and computed tomography plus serum amyloid A protein in staging rectal cancer.

Yun Yang1, Tian Tang2, Wei Peng3, Lin Xia1, Xiaodong Wang1, Baofeng Duan4, Ye Shu5.   

Abstract

BACKGROUND: Recently identified class of microRNAs (miRNAs) provided a new insight in cancer research. As a member of miRNAs family, miR-155 expression demonstrated the correlation with tumor stage. Thus, its expression level can be potentially used for staging rectal tumors. The aim of this study was to systematically evaluate the potential abilities of miR-155 in preoperatively N staging.
MATERIALS AND METHODS: Expression of miR-155 was detected and quantitated in rectal cancer tissues and in adjacent nonmalignant tissues from 40 patients by TaqMan MicroRNA assays. Preoperative enhanced computed tomography (CT) scan, serum amyloid A protein (SAA), carcinoembryonic antigen (CEA), and postoperative pathologic biopsy were performed.
RESULTS: A significant overexpression of miR-155 was observed in rectal carcinoma tissues (0.137 ± 0.095 versus 0.093 ± 0.091, P = 0.043). High expression of miR-155 in N1-2 (0.09 ± 0.038 versus 0.183 ± 0.111, P = 0.001) and III and IV stages (0.091 ± 0.039 versus 0.178 ± 0.111, P = 0.002) presented its potential correlation with N and tumor-node-metastasis combined stages. Receiver operating characteristics curve analysis showed that miR-155 could discriminate N0 from N1-2 with 85.0% sensitivity and 85.0% specificity at the cutoff value of 0.125. miR-155 and CT had nearly equal performances in sensitivity (0.850 versus 0.700, P = 0.450) and specificity (0.850 versus 0.550, P = 0.077) in predicting N1-2 stage. Compared with CT + SAA, miR-155 had similar sensitivity (0.850 versus 0.950, P = 0.617) but higher specificity (0.750 versus 0.200, P = 0.015) for lymph node assessment.
CONCLUSIONS: Increase in the expression of miR-155 might represent a potential valuable marker for rectal carcinoma N and combined tumor-node-metastasis staging.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CT; N stage; Rectal cancer; SAA; miR-155; microRNA

Mesh:

Substances:

Year:  2014        PMID: 25261908     DOI: 10.1016/j.jss.2014.08.040

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  5 in total

1.  MicroRNA-155 hallmarks promising accuracy for the diagnosis of various carcinomas: results from a meta-analysis.

Authors:  Chuancheng Wu; Qiuyan Liu; Baoying Liu
Journal:  Dis Markers       Date:  2015-03-30       Impact factor: 3.434

Review 2.  MicroRNAs in colorectal carcinoma--from pathogenesis to therapy.

Authors:  Yudan Chi; Dongming Zhou
Journal:  J Exp Clin Cancer Res       Date:  2016-03-10

Review 3.  Translational Potential of MicroRNAs for Preoperative Staging and Prediction of Chemoradiotherapy Response in Rectal Cancer.

Authors:  Tana Machackova; Vladimir Prochazka; Zdenek Kala; Ondrej Slaby
Journal:  Cancers (Basel)       Date:  2019-10-12       Impact factor: 6.639

Review 4.  Reference Genes for qPCR-Based miRNA Expression Profiling in 14 Human Tissues.

Authors:  Yulia Andreevna Veryaskina; Sergei Evgenievich Titov; Igor Fyodorovich Zhimulev
Journal:  Med Princ Pract       Date:  2022-03-30       Impact factor: 2.132

5.  MicroRNA Expression Profiling to Identify and Validate Reference Genes for the Relative Quantification of microRNA in Rectal Cancer.

Authors:  Anne Haahr Mellergaard Eriksen; Rikke Fredslund Andersen; Niels Pallisgaard; Flemming Brandt Sørensen; Anders Jakobsen; Torben Frøstrup Hansen
Journal:  PLoS One       Date:  2016-03-03       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.